As part of our ongoing series focussing on new registrations in Australia, we have added a product review of the use of Ofatumumab for the treatment of Multiple Sclerosis.
This review discusses early treatment, NEDA as a treatment target, pharmacological properties, mechanism of action and major studies featuring Ofatumumab. It also provides commentary and recommendations from Associate Professor Anneke van der Walt, a Neurologist and Head of MS and Neuroimmunology Unit and Neuro-ophthalmology Service at Alfred Health, Melbourne.
Please login below to download this issue (PDF)